Successful program to prevent aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin.
Aspergillus infections in the pediatric bone marrow transplant (BMT) patients are usually fatal. We began the use of a prophylactic nasal spray of amphotericin in 1990. This nasal spray was provided in addition to low-dose intravenous amphotericin. During the time of this study, the number of fatal cases of aspergillus in the pediatric BMT population was reduced significantly from 13.8% to 1.8% (P < 0.0025) thereby suggesting that the use of nasal amphotericin in this population helps to prevent fatal aspergillus infections. The lack of significant side-effects and the ease of administration make this a very helpful preventive measure in the supportive care of pediatric bone marrow transplant patients.
Trigg
M E
ME
Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City 52242, USA.
Morgan
D
D
Burns
T L
TL
Kook
H
H
Rumelhart
S L
SL
Holida
M D
MD
Giller
R H
RH
D000281:Administration, Intranasal; D000293:Adolescent; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000517:prevention & control*; D001230:Aspergillus; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous
D000935:Antifungal Agents; D000666:Amphotericin B